Shumeiqi Chengdu Biotechnology

Shumeiqi Chengdu Biotechnology is a specialized biopharmaceutical firm based in China, focusing on the development and manufacture of complex peptide APIs and intermediates. The company has established a significant presence in the metabolic disease space, particularly through its production capabilities for GLP-1, GIP, and glucagon receptor agonists. Shumeiqi provides high-purity materials for global research and commercial applications, supporting the development of treatments for obesity and type 2 diabetes. Their technical expertise includes solid-phase and liquid-phase peptide synthesis, as well as advanced purification technologies. The company operates out of the Chengdu High-tech Zone, serving as a key supplier in the global peptide drug supply chain.